CN103497205B - 一种头孢噻吩钠的新晶型及其制备方法 - Google Patents
一种头孢噻吩钠的新晶型及其制备方法 Download PDFInfo
- Publication number
- CN103497205B CN103497205B CN201310439087.8A CN201310439087A CN103497205B CN 103497205 B CN103497205 B CN 103497205B CN 201310439087 A CN201310439087 A CN 201310439087A CN 103497205 B CN103497205 B CN 103497205B
- Authority
- CN
- China
- Prior art keywords
- glaxo
- new crystal
- preparation
- crystal
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 16
- 238000002425 crystallisation Methods 0.000 claims description 13
- 230000008025 crystallization Effects 0.000 claims description 13
- 239000012043 crude product Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 8
- 238000007086 side reaction Methods 0.000 abstract description 4
- 230000007423 decrease Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 24
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 17
- 229960003016 cefoxitin sodium Drugs 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 206010013786 Dry skin Diseases 0.000 description 6
- 229960004489 cefonicid Drugs 0.000 description 6
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 6
- 230000006837 decompression Effects 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 229960002682 cefoxitin Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010087702 Penicillinase Proteins 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229950009506 penicillinase Drugs 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010040400 serum sickness Diseases 0.000 description 2
- 201000005060 thrombophlebitis Diseases 0.000 description 2
- AJYXPNIENRLELY-UHFFFAOYSA-N 2-thiophen-2-ylacetyl chloride Chemical compound ClC(=O)CC1=CC=CS1 AJYXPNIENRLELY-UHFFFAOYSA-N 0.000 description 1
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- ODFJOVXVLFUVNQ-UHFFFAOYSA-N acetarsol Chemical compound CC(=O)NC1=CC([As](O)(O)=O)=CC=C1O ODFJOVXVLFUVNQ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
- C07D501/34—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/12—Separation; Purification
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
序号 | 2THETA | Height | FWHM | D-Spacing | Rel.Int |
1 | 3.5671 | 329.34 | 0.1476 | 23.27930 | 28.76 |
2 | 5.9673 | 264.26 | 0.1476 | 20.33782 | 96.94 |
3 | 7.8632 | 397.55 | 0.1968 | 16.59647 | 88.37 |
4 | 9.3543 | 389.42 | 0.1476 | 13.48966 | 36.85 |
5 | 10.6972 | 739.84 | 0.1476 | 10.64826 | 8.76 |
6 | 12.8933 | 1668.95 | 0.1476 | 9.67383 | 36.52 |
7 | 14.3276 | 899.44 | 0.1476 | 8.66341 | 45.26 |
8 | 15.8473 | 518.18 | 0.1968 | 8.46925 | 68.75 |
9 | 16.4239 | 358.56 | 0.2460 | 8.15365 | 28.26 |
10 | 16.9842 | 565.35 | 0.1968 | 7.88552 | 8.23 |
11 | 17.8633 | 1296.33 | 0.1476 | 7.02837 | 16.24 |
12 | 18.7376 | 677.38 | 0.1968 | 6.83544 | 3.51 |
13 | 19.6034 | 341.75 | 0.2460 | 6.37861 | 26.31 |
14 | 20.3855 | 1472.16 | 0.1476 | 5.96736 | 10.77 |
15 | 20.9853 | 4135.05 | 0.1476 | 5.58236 | 22.31 |
16 | 21.3583 | 2600.11 | 0.1968 | 5.21351 | 6.32 |
17 | 22.7638 | 1495.25 | 0.2460 | 4.83625 | 9.63 |
18 | 23.5466 | 438.58 | 0.1476 | 4.29385 | 17.33 |
19 | 24.3892 | 847.43 | 0.1476 | 4.00394 | 23.58 |
20 | 25.4013 | 539.35 | 0.2046 | 3.83624 | 9.86 |
21 | 25.9366 | 373.24 | 0.1476 | 3.66367 | 8.63 |
22 | 26.4832 | 478.36 | 0.2046 | 3.46356 | 6.22 |
23 | 27.6632 | 1245.33 | 0.1476 | 3.38119 | 7.86 |
24 | 28.0318 | 738.25 | 0.1968 | 3.28365 | 6.18 |
25 | 28.3682 | 4663.15 | 0.1476 | 3.20135 | 3.86 |
26 | 29.5632 | 1586.38 | 0.2460 | 3.13085 | 5.66 |
27 | 30.4965 | 987.62 | 0.1968 | 3.07263 | 3.54 |
28 | 31.0029 | 2675.33 | 0.1476 | 2.88362 | 7.22 |
29 | 31.8635 | 1459.21 | 0.1476 | 2.80229 | 19.35 |
30 | 32.0518 | 963.54 | 0.1476 | 2.74328 | 11.17 |
31 | 32.6325 | 624.27 | 0.1476 | 2.72535 | 18.26 |
32 | 33.0109 | 235.25 | 0.2460 | 2.70267 | 15.33 |
33 | 33.9645 | 1373.56 | 0.1968 | 2.68013 | 8.36 |
34 | 34.5638 | 466.34 | 0.1476 | 2.66182 | 9.35 |
35 | 35.0645 | 588.35 | 0.1476 | 2.59362 | 7.28 |
36 | 36.8725 | 276.63 | 0.2460 | 2.68725 | 4.62 |
37 | 37.8934 | 2315.82 | 0.1968 | 2.51364 | 6.34 |
38 | 39.1782 | 6215.17 | 0.1968 | 2.30318 | 5.25 |
39 | 41.9816 | 2426.38 | 0.1476 | 2.15371 | 3.82 |
40 | 43.0718 | 1523.82 | 0.1476 | 2.08388 | 6.18 |
41 | 44.7637 | 918.96 | 0.1968 | 1.98661 | 4.28 |
42 | 45.9117 | 486.34 | 0.1476 | 1.90734 | 4.06 |
43 | 47.0302 | 198.42 | 0.2460 | 1.86325 | 3.26 |
44 | 48.3639 | 3977.22 | 0.1476 | 1.82372 | 2.83 |
45 | 49.7683 | 2265.35 | 0.2460 | 1.80325 | 1.98 |
46 | 51.2759 | 1439.53 | 0.1476 | 1.73256 | 1.57 |
47 | 52.6894 | 623.35 | 0.1476 | 1.72009 | 2.05 |
48 | 53.4468 | 5362.77 | 0.1968 | 1.70356 | 1.78 |
49 | 54.0685 | 4215.38 | 0.1476 | 1.68457 | 2.36 |
50 | 54.9361 | 2016.42 | 0.2460 | 1.67309 | 3.07 |
51 | 55.4832 | 922.83 | 0.1476 | 1.62344 | 1.70 |
52 | 56.7635 | 523.31 | 0.2460 | 1.61068 | 3.56 |
53 | 57.8362 | 229.24 | 0.1476 | 1.60335 | 1.87 |
54 | 58.1432 | 321.35 | 0.1476 | 1.59667 | 1.38 |
55 | 59.0065 | 259.58 | 0.1476 | 1.57492 | 1.17 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310439087.8A CN103497205B (zh) | 2013-09-24 | 2013-09-24 | 一种头孢噻吩钠的新晶型及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310439087.8A CN103497205B (zh) | 2013-09-24 | 2013-09-24 | 一种头孢噻吩钠的新晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103497205A CN103497205A (zh) | 2014-01-08 |
CN103497205B true CN103497205B (zh) | 2015-10-07 |
Family
ID=49862486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310439087.8A Active CN103497205B (zh) | 2013-09-24 | 2013-09-24 | 一种头孢噻吩钠的新晶型及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103497205B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106344528A (zh) * | 2015-05-15 | 2017-01-25 | 烟台市华文欣欣医药科技有限公司 | 一种治疗敏感菌感染性疾病的药物盐酸头孢他美酯片剂组合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3218318A (en) * | 1962-08-31 | 1965-11-16 | Lilly Co Eli | 7-heterocyclic-substituted-acylamido cephalosporins |
JPS5254017A (en) * | 1975-10-28 | 1977-05-02 | Toyo Jozo Co Ltd | Crystallization of sodium salt of cephalothin |
JPH05254017A (ja) * | 1991-11-11 | 1993-10-05 | Canon Aptecs Kk | ラミネート装置 |
-
2013
- 2013-09-24 CN CN201310439087.8A patent/CN103497205B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103497205A (zh) | 2014-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0581552A2 (en) | Triazolylthiomethylthio cephalosporin hyrochloride, its crystalline hydrate and the production of the same | |
CN102659818B (zh) | 一种盐酸头孢替安晶体化合物及其制备方法及含该化合物的药物组合物 | |
CN102268018A (zh) | 头孢克肟的结晶方法 | |
CN102875574A (zh) | 头孢曲松钠晶型及其制备方法 | |
CN103524532B (zh) | 一种头孢唑肟钠化合物晶型、制备方法及其药物制剂 | |
CN103497205B (zh) | 一种头孢噻吩钠的新晶型及其制备方法 | |
CN104644630A (zh) | 一种注射用阿莫西林钠舒巴坦钠制剂及其制备方法 | |
CN103012434A (zh) | 一种头孢硫脒化合物晶体其制备方法及其药物组合物 | |
CN104910186A (zh) | 一种头孢硫脒化合物 | |
CN103467494B (zh) | 一种头孢地尼的新晶型及其制备方法 | |
CN102268024A (zh) | 比阿培南新晶型及其合成方法 | |
CN103304582B (zh) | 一种头孢西丁钠的化合物、其制备方法及其药物组合物 | |
CN103601739A (zh) | 一种头孢西丁钠化合物及其制备方法 | |
CN102942577B (zh) | 一种含有头孢西丁钠化合物的药物组合物 | |
CN109553626B (zh) | 一种头孢唑肟钠的精制方法 | |
CN103965215B (zh) | 一种头孢唑林钠化合物及其无菌粉针 | |
CN106317080A (zh) | 一种采用耦合结晶技术制备的头孢他啶化合物及其制剂 | |
CN103520120B (zh) | 一种替比培南匹伏酯组合物颗粒剂 | |
CN102977101A (zh) | 多尼培南一水合物、其药物组合物、其制备方法和用途 | |
WO2017140073A1 (zh) | 一种采用粒子过程晶体产品分子组装与形态优化技术的头孢硫脒新晶型化合物及制剂 | |
CN104622695A (zh) | 一种注射用头孢西丁钠粉针制剂 | |
CN104530082A (zh) | 头孢硫脒化合物 | |
CN105541871B (zh) | 一种头孢美唑晶型化合物及其制备方法 | |
CN109096309B (zh) | 一种43/4水头孢他啶化合物及其药物组合物 | |
CN105461739B (zh) | 结晶头孢嗪脒钠及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: Seven of 276017 Shandong province Linyi city Luozhuang District No. 18 Applicant after: Shandong Luo Xin Pharmaceutical Group Plc Address before: Seven of 276017 Shandong province Linyi city Luozhuang District No. 18 Applicant before: SHANDONG LUOXIN PHARMACY STOCK Co., LTD. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHANDONG LUOXIN PHARMACY STOCK CO., LTD. TO: SHANDONG LUOXIN PHARMACY GROUP CO., LTD. |
|
ASS | Succession or assignment of patent right |
Owner name: SHANDONG YUXIN PHARMACEUTICAL CO., LTD. SHANDONG H Effective date: 20150906 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Hua Inventor after: Song Yuwei Inventor after: Yang Lijuan Inventor after: Wang Jinxing Inventor after: Han Houliang Inventor before: Li Hua Inventor before: Song Yuwei Inventor before: Yang Lijuan Inventor before: Wang Jinxing |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LI HUA SONG YUWEI YANG LIJUAN WANG JINXING TO: LI HUA SONG YUWEI YANG LIJUAN WANG JINXING HAN HOULIANG |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150906 Address after: Seven of 276017 Shandong province Linyi city Luozhuang District No. 18 Applicant after: Shandong Luo Xin Pharmaceutical Group Plc Applicant after: Shandong Yu Xin pharmaceutcal corporation, Ltd Applicant after: SHANDONG HENGXIN PHARMACEUTICAL CO., LTD. Address before: Seven of 276017 Shandong province Linyi city Luozhuang District No. 18 Applicant before: Shandong Luo Xin Pharmaceutical Group Plc |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 276017 18 Luo Qi Road, Luozhuang District, Linyi, Shandong Co-patentee after: Shandong Yu Xin pharmaceutcal corporation, Ltd Patentee after: Shandong Luo Xin Pharmaceutical Group Plc Co-patentee after: Shandong Luo Xin Pharmaceutical Group Plc Address before: 276017 18 Luo Qi Road, Luozhuang District, Linyi, Shandong Co-patentee before: Shandong Yu Xin pharmaceutcal corporation, Ltd Patentee before: Shandong Luo Xin Pharmaceutical Group Plc Co-patentee before: SHANDONG HENGXIN PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 276017 18 Luo Qi Road, Luozhuang District, Linyi, Shandong Co-patentee after: Shandong Yu Xin pharmaceutcal corporation, Ltd Patentee after: Shandong Luo Xin Pharmaceutical Group Plc Co-patentee after: Shandong Luoxin Pharmaceutical Group Hengxin Pharmacy Co., Ltd. Address before: 276017 18 Luo Qi Road, Luozhuang District, Linyi, Shandong Co-patentee before: Shandong Yu Xin pharmaceutcal corporation, Ltd Patentee before: Shandong Luo Xin Pharmaceutical Group Plc Co-patentee before: SHANDONG HENGXIN PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |